These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

577 related items for PubMed ID: 21271613

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer.
    Fizazi K, Higano CS, Nelson JB, Gleave M, Miller K, Morris T, Nathan FE, McIntosh S, Pemberton K, Moul JW.
    J Clin Oncol; 2013 May 10; 31(14):1740-7. PubMed ID: 23569308
    [Abstract] [Full Text] [Related]

  • 3. Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone.
    Nelson JB, Fizazi K, Miller K, Higano C, Moul JW, Akaza H, Morris T, McIntosh S, Pemberton K, Gleave M.
    Cancer; 2012 Nov 15; 118(22):5709-18. PubMed ID: 22786751
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Zibotentan for the treatment of castrate-resistant prostate cancer.
    Shepard DR, Dreicer R.
    Expert Opin Investig Drugs; 2010 Jul 15; 19(7):899-908. PubMed ID: 20497097
    [Abstract] [Full Text] [Related]

  • 9. A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer.
    Armstrong AJ, Creel P, Turnbull J, Moore C, Jaffe TA, Haley S, Petros W, Yenser S, Gockerman JP, Sleep D, Hurwitz H, George DJ.
    Clin Cancer Res; 2008 Oct 01; 14(19):6270-6. PubMed ID: 18829508
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer.
    Schelman WR, Liu G, Wilding G, Morris T, Phung D, Dreicer R.
    Invest New Drugs; 2011 Feb 01; 29(1):118-25. PubMed ID: 19763400
    [Abstract] [Full Text] [Related]

  • 12. Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center.
    Zhang HL, Ye DW, Yao XD, Dai B, Zhang SL, Shen YJ, Zhu Y, Zhang W.
    Urol Int; 2007 Feb 01; 79(4):307-11. PubMed ID: 18025847
    [Abstract] [Full Text] [Related]

  • 13. Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer.
    Fleming MT, Sonpavde G, Kolodziej M, Awasthi S, Hutson TE, Martincic D, Rastogi A, Rousey SR, Weinstein RE, Galsky MD, Berry WR, Wang Y, Boehm KA, Asmar L, Rauch MA, Beer TM.
    Clin Genitourin Cancer; 2012 Mar 01; 10(1):6-14. PubMed ID: 22340631
    [Abstract] [Full Text] [Related]

  • 14. Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer.
    Dreicer R, Petrylak D, Agus D, Webb I, Roth B.
    Clin Cancer Res; 2007 Feb 15; 13(4):1208-15. PubMed ID: 17317831
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure.
    Meulenbeld HJ, Bleuse JP, Vinci EM, Raymond E, Vitali G, Santoro A, Dogliotti L, Berardi R, Cappuzzo F, Tagawa ST, Sternberg CN, Jannuzzo MG, Mariani M, Petroccione A, de Wit R.
    BJU Int; 2013 Jan 15; 111(1):44-52. PubMed ID: 22928785
    [Abstract] [Full Text] [Related]

  • 17. High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study.
    Tiffany NM, Ryan CW, Garzotto M, Wersinger EM, Beer TM.
    J Urol; 2005 Sep 15; 174(3):888-92. PubMed ID: 16093981
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators.
    Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Redfern CH, Fehrenbacher L, Saleh MN, Waterhouse DM, Carducci MA, Vicario D, Dreicer R, Higano CS, Ahmann FR, Chi KN, Henner WD, Arroyo A, Clow FW, ASCENT Investigators.
    J Clin Oncol; 2007 Feb 20; 25(6):669-74. PubMed ID: 17308271
    [Abstract] [Full Text] [Related]

  • 20. Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer.
    Mardjuadi F, Medioni J, Kerger J, D'Hondt L, Canon JL, Duck L, Musuamba F, Oudard S, Clausse M, Moxhon A, Machiels JP.
    Cancer Chemother Pharmacol; 2012 Aug 20; 70(2):293-303. PubMed ID: 22752248
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.